What Texas Diagnostic Laboratories does

Texas Diagnostic Laboratories (TDL) is a privately held, Houston, Texas-based clinical diagnostic laboratory founded during the COVID-19 pandemic, with CLIA certification (CLIA# 45D2196313) and CDPH accreditation. The company operates Patient Service Centres across 24 US states and offers five core test categories: pharmacogenomic (PGx) panels covering psychiatry, pain, cardiovascular, and a 159+ medication comprehensive panel; toxicology testing with 48-metabolite customizable panels via oral fluid or urine (hair testing in development); routine blood work including chemistry, hematology, hormones, and metabolic panels; next-generation sequencing (NGS) for cancer, cardiology/pulmonology, neurodegenerative disease, and non-invasive prenatal testing; and PCR-based infectious disease detection spanning wound, UTI, STI, respiratory, and GI pathogens with 24–48 hour turnaround and antibiotic resistance gene detection.

The underlying technology is built on standard clinical laboratory methods — PCR, NGS, immunoassays — with pharmacogenomic interpretation grounded in CPIC, PharmGKB, and FDA guidelines. Products are delivered through a hybrid go-to-market: direct-to-consumer cash-pay (PGx panels priced $199–$299, COVID-19 tests $50–$280, 10% bulk discount on 10+ units), insurance-billed testing, walk-in Patient Service Centres, online appointment booking, and B2B clinical testing partnerships with healthcare providers and organizations, with EMR integration including Practice Fusion.

TDL's revenue mechanics are primarily transactional per-test fees, supplemented by insurance reimbursement and provider-channel professional services. The company has also engaged in international pandemic-response work, notably a 2022 partnership with Africa CDC on the PACT (Partnership to Accelerate COVID-19 Testing) initiative contributing 200 logistics access points across African Union Member States. Leadership is founder-led, with Maria Kriss as Founder, Chris Wensel as Co-founder, Richy Muldoone as Medical Director, and Zach Liu, MD as Lab Director.

Name

Texas Diagnostic Laboratories

Legal name

Texas Diagnostic Laboratories

Website

https://txdxlabs.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Texas Diagnostic Laboratories is a Houston-based, CLIA-certified clinical lab offering pharmacogenomic panels, toxicology, routine blood work, NGS genetic testing, and PCR infectious disease detection to consumers and healthcare providers across 24 US states.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Independent Diagnostic Testing Facilities (IDTFs) & Multi-Specialty Diagnostic Centers (HLAFAKAN), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

Keywords

• Clinical diagnostic laboratory
• Pharmacogenomic testing
• Infectious disease PCR
• Next generation sequencing
• Toxicology screening

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Direct-to-Consumer Diagnostic Testing: Patients purchase pharmacogenomic and other test kits directly online or book lab visits for testing services. Products like Psychiatry PGx Panel ($199) and Comprehensive PGx Panel ($299) are sold as one-time purchases.
2. Healthcare Provider Clinical Testing: TDL provides testing services ordered by healthcare providers and healthcare organizations, partnering with clinical practices for diagnostic laboratory services.
3. Insurance-Billed Testing: Many tests are covered under provincial/state health insurance plans, with billing processed through insurance providers for eligible tests.
4. Cash/Self-Pay Services: Direct-pay testing services including pharmacogenomic panels, routine blood work, and specialized tests available without insurance requirements.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

Texas Diagnostic Laboratories is a CLIA-certified clinical diagnostics laboratory offering pharmacogenomic testing panels (Psychiatry, Pain, Cardiovascular, and Comprehensive), PCR-based infectious disease detection, routine blood work, customizable toxicology screening, and next-generation sequencing genetic testing. Services are delivered both directly to patients via walk-in Patient Service Centres and e-commerce purchased PGx kits, and to healthcare providers and organizations through clinical partnerships with EMR-integrated reporting. The company emphasizes fast turnaround times, lifelong genetic insights, and direct patient access to results.

Product overview

Texas Diagnostic Laboratories offers a comprehensive suite of diagnostic testing services organized into five main categories: Pharmacogenomic (PGx) Testing with four distinct panels (Psychiatry, Pain, Cardiovascular, and Comprehensive), Toxicology with customizable panels covering 48 metabolites, Routine Blood Work including chemistry/hormone/hematology/metabolic tests, Next Generation Sequencing (NGS) for genetic testing, and Infectious Disease Detection via PCR testing. The Pharmacogenomic panels range from specialty-focused ($199 each for Psychiatry, Pain, and Cardiovascular) to a comprehensive panel covering 159+ medications ($299). All testing services emphasize fast turnaround times, direct patient results access, and support for healthcare providers in making informed medication and treatment decisions.

Differentiator

Problem solved

Functional benefit

Products and services

• Psychiatry Pharmacogenomic (PGx) Panel Pharmacogenomic test panel analyzing genetic variants (COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6) to guide psychiatric medication selection including antidepressants, antipsychotics, anxiolytics, and ADHD medications; turnaround 10-14 days, priced at $199.
• Pain Pharmacogenomic (PGx) Panel Pharmacogenomic panel analyzing genes (COMT, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4) related to pain perception, opioid metabolism, NSAID response, and pain management medications; covers 23+ pain-related medications including opioids, NSAIDs, and muscle relaxants.
• Cardiovascular Pharmacogenomic (PGx) Panel Pharmacogenomic panel evaluating genes (APOE, CYP2C19, CYP2C9, CYP2D6, CYP3A4, SLCO1B1, VKORC1) involved in cardiovascular drug metabolism including antiplatelets, statins, beta-blockers, antiarrhythmics, and anticoagulants; covers 27+ medications, turnaround 10-14 days.
• Comprehensive Pharmacogenomic (PGx) Panel Comprehensive pharmacogenomic panel analyzing 14 genes (APOE, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, F2, F5, MTHFR, SLCO1B1, VKORC1) covering medications across psychiatry, pain management, oncology, cardiology, gastroenterology, immunology, infectious disease, neurology, and more; covers 159+ medications and is priced at $299.
• Toxicology Testing Customizable toxicology panels for controlled medication compliance monitoring, covering 48 metabolites; available via oral fluid or urine collection with hair testing in development; supports clinician decision-making for compliance.
• Routine Blood Work Routine blood testing including chemistries, hormones, hematology, and metabolic panels delivered with fast turnaround times for patient and provider use.
• Next Generation Sequencing (NGS) Genetic Testing Advanced genomic testing via next-generation sequencing covering cancer, cardiology/pulmonology, neurodegenerative disease, and non-invasive prenatal testing (NIPT), enabling inherited genetic risk evaluation.
• Infectious Disease Detection (PCR Testing) PCR-based infectious disease testing covering wound, urinary tract infection, sexually transmitted infection, respiratory pathogen panel (including COVID-19), and gastrointestinal pathogens; includes culture testing and antibiotic resistance gene detection; PCR turnaround 24-48 hours and culture turnaround 3-7 days.

Quantifiable outcome

• 97% customer satisfaction rate
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Africa CDC (Africa Centres for Disease Control and Prevention)coreStrategic or Co-development Partner · 25 April 2022TDL supported Africa CDC's PACT initiative (Partnership to Accelerate COVID-19 Testing) to increase COVID-19 testing capacity across African Union Member States, with a goal to test 10 million Africans. TDL contributed logistics network expertise with 200 access points across the continent to help track COVID-19 variants and minimize social disruption and economic consequences.
• Africa CDC / African UnioncoreStrategic or Co-development PartnerContinental strategy partnership focused on preventing severe illness and death from COVID-19 across Africa, coordinated by Africa CDC in collaboration with the Africa Task Force for Coronavirus (AFTCOR). AfroChampions pan-African business leadership network served as strategic partner.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Genomind: Specialized pharmacogenomic testing company focused on mental health medications, including the GeneSight Psychotropic test. Directly comparable to TDL's Psychiatry PGx Panel, addressing the same psychiatrist/prescriber and patient market for gene-guided psychiatric prescribing.
• Natera: Specialized genetic testing company with leading NIPT (Panorama) and oncology offerings. Comparable to TDL's NIPT and hereditary cancer NGS testing, with substantially more clinical-trial evidence and physician adoption.
• GeneDx: Clinical genomics company offering exome/genome sequencing, rare disease, and hereditary testing. Comparable on the NGS side, with deeper pediatric/rare-disease specialization and stronger hospital-system contracts.
• Invitae: Genetic information company offering hereditary cancer, reproductive health, and PGx panels. Overlaps with TDL's NGS and Comprehensive PGx Panel, with a stronger digital/consumer health platform and broader test menu.
• Color Health: Population health and DTC genetic testing company offering hereditary cancer, PGx, and employer-sponsored screening. Highly comparable hybrid DTC + clinical model, though at much larger scale and with more public-health and employer contracts.

Broad incumbents

• Sonic Healthcare USA: International reference lab operator with US presence offering routine, anatomic, and specialty diagnostics. Comparable to TDL on routine and specialty clinical testing, with redundant regional lab infrastructure that TDL lacks.
• Labcorp: Largest US clinical reference lab, offering routine diagnostics, specialty/esoteric testing, and PGx. Directly comparable on the bulk of TDL's menu, with deeper payer relationships, a national service-centre footprint, and a much larger sales force.
• BioReference Laboratories: Full-service clinical reference lab (an OPKO Health subsidiary) offering routine, esoteric, and specialty diagnostics. Comparable to TDL on the broad test menu and B2B provider channel, with substantially more scale and legacy payer contracts.
• Myriad Genetics: Established molecular diagnostics company offering hereditary cancer, pharmacogenomic, and NIPT testing. Comparable to TDL on the NGS/Pgx/oncology side, with deeper clinical evidence, broader payer coverage, and a much larger commercial organization.
• Quest Diagnostics: National reference laboratory offering routine blood work, toxicology, infectious disease PCR, and increasingly PGx. Direct competitor on TDL's routine and PCR test menu, with nationwide patient service centres, EMR integration, and dominant insurance contracts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Txdx.Lab
• Instagraminstagram.com/txdx.lab
• LinkedInlinkedin.com/company/texas-diagnostic-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Texas Diagnostic Laboratories